Adamas Pharmaceuticals soared in midday trading on Dec. 23, giving the gift of positive late-stage results to investors for its Parkinson's disease treatment.
Adamas Readies NDA After Positive Phase III
More from Neurological
More from Therapy Areas
• By
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
• By
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
• By
The company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.